Electrochemical biosensors have shown immense potential for point-of-care biosensors; however, the detection of rare biomarkers like microRNA often necessitates complex and multi-step approaches involving enzymes and amplification strategies. Under this research direction, the BioMAD lab has developed two robust amplification-free electrochemical biosensing platforms for microRNA detection based on PNA-functionalized 2D nanomaterials, including laser-scribed graphene. Our biosensors can outperform traditional methods, achieving attomolar limits of detection, high sequence specificity, and a large dynamic range at the point-of-care. Importantly, these platforms can be programmed to inform important clinical decisions, including the diagnosis or prognosis of cancer and other age-associated diseases.